综合色婷婷,久久av老司机精品网站导航,午夜精品久久久久9999,欧美日韩xxx

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73197KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3
名稱 KIF5B(E15)-RET(E12) V804E/BaF3
型號(hào) CBP73197
報(bào)價(jià)
特點(diǎn) KIF5B(E15)-RET(E12) [V804E]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73197
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804E]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


2. Sanger of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


3. Anti-proliferation assay

KIF5B(E15)-RET(E12) V804E/BaF3


Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804E Cells (C1).





如果你對(duì)CBP73197KIF5B(E15)-RET(E12) V804E/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
美国大型操逼| 欧美好吊操视频在线免费观看| 伊人亚洲五月天| 人人肉揉揉| 插b视频免费看| 五月精品一区二区在线| 91秦先生视频播放在线| 亚州αv高清| 日韩欧美国产视频大全| 中文字幕久荜欧美在线观看 | 亚洲中文字幕五区| 91淫黄大片黄| 丝袜美腿教师av在线| 黄在线中文| 五月妞婷婷操逼| 国产精品乱伦1区| 嘉荫县| 亚洲 日韩 欧美 亚洲 综合 另类| 大香蕉尤物国产视频| 欧美一区二区三区淫妇放荡视频| 在线日韩偷情视频网站| 婷婷视频偷拍基地| 美女写真国产视频美女| 欧美乱妇在线欧美视频| 北京少妇鸡巴视频| 不卡你懂的| 深爱激情播| 欧美大鸡巴对大逼逼| 任我草在线观看视频| 啪啪福利一区| www欧美美女搞鸡巴| 天天天玩夜夜夜爽| 能看的日B视频| 欧日韩一级免费视频| 亚洲AV无码无一区二区在线| 台湾佬性少妇| 黄片区免费加长版| 被大鸡巴插到高潮高清视频在线观看 | 久操免费视频| 欧美一区二区三区96久久久| 结衣更新亚洲|